Opportunities and challenges in using real-world data for health care

2020/02/02 by Vivek A. Rudrapatna, Atul J. Butte · 26 citations
Economics, Econometrics and Finance · Medicine · Mathematics · #Health Systems, Economic Evaluations, Quality of Life #Medication Adherence and Compliance #Statistical Methods in Clinical Trials

paper · pdf · doi:10.1172/jci129197

Abstract

Real-world data (RWD) continue to emerge as a new source of clinical evidence. Although the best-known use case of RWD has been in drug regulation, RWD are being generated and used by many other parties, including biopharmaceutical companies, payors, clinical researchers, providers, and patients. In this Review, we describe 21 potential uses for RWD across the spectrum of health care. We also discuss important challenges and limitations relevant to the translation of these data into evidence.

Cited by

• Rehabilitation services and related health databases, Japan
• Accuracy of medical billing data against the electronic health record in the measurement of colorectal cancer screening rates. [europepmc]
• Utility of routinely collected electronic health records data to support effectiveness evaluations in inflammatory bowel disease: a pilot study of tofacitinib. [europepmc]
• Gaps in standards for integrating artificial intelligence technologies into ophthalmic practice. [europepmc]
• Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease. [europepmc]
• A Framework for Augmented Intelligence in Allergy and Immunology Practice and Research-A Work Group Report of the AAAAI Health Informatics, Technology, and Education Committee. [europepmc]
• Selecting Privacy-Enhancing Technologies for Managing Health Data Use. [europepmc]
• Genetically predicted on-statin LDL response is associated with higher intracerebral haemorrhage risk. [europepmc]
• Short-acting β 2 -agonist prescription patterns in patients with asthma in Turkey: results from SABINA III. [europepmc]
• A Vascular Quality Initiative frailty assessment predicts postdischarge mortality in patients undergoing arterial reconstruction. [europepmc]
• How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer. [europepmc]
• Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. [europepmc]
• From Genes to Geography, from Cells to Community, from Biomolecules to Behaviors: The Importance of Social Determinants of Health. [europepmc]
• Rehabilitation services and related health databases, Japan. [europepmc]
• The value of real world evidence: The case of medical cannabis. [europepmc]
• Real-World Evidence: A Primer. [europepmc]
• Creation of an ustekinumab external control arm for Crohn's disease using electronic health records data: A pilot study. [europepmc]
• Assessing Heterogeneity of Treatment Effect in Real-World Data. [europepmc]
• Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance. [europepmc]
• Artificial Intelligence: Exploring the Future of Innovation in Allergy Immunology. [europepmc]
• Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials. [europepmc]
• The promise of digital healthcare technologies. [europepmc]
• A causal roadmap for generating high-quality real-world evidence. [europepmc]
• Using routinely collected clinical data for circadian medicine: A review of opportunities and challenges. [europepmc]
• Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases. [europepmc]
• Socio-ethical challenges and opportunities for advancing diversity, equity, and inclusion in digital medicine. [europepmc]

Related

• From data to evidence: why administrative databases alone cannot measure real-world effectiveness in rare diseases – the case of chronic myeloid leukaemia
• Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective
• Real‐world evidence and observational studies: Methodological challenges in clinical research
• Harnessing electronic health records for real-world evidence
• The FDA Sentinel Real World Evidence Data Enterprise (RWE‐DE)